Michael Gibney

Scientists at the Oak Crest Institute of Science have shown in a first-of-its-kind result that an intravaginal ring could protect against HIV completely when delivered topically in animal tests.

Researchers at Case Western University in Cleveland and MIT have combined forces around a new nanoparticle from a plant virus that shrunk tumors in vivo by delivering an unapproved chemo drug, outpacing the more common cisplatin in triple-negative breast cancer.

Intec Pharma, maker of the Accordian Pill delivery platform, secured a $5.2 million grant from the Israeli government to support late-stage R&D for its Parkinson’s candidate, which makes use of the oral technology.

5AM Ventures, the prolific biotech and drug delivery investor out of Menlo Park, CA, has raked in $285 million for its fifth fund, according to an SEC filing.

Carnegie Mellon scientists are making use of carbon nanotubes for drug delivery. The tubes are made of very simple components so that they are more readily taken up by cells.

Researchers from Cornell University have developed a combination therapy to treat cancers such as prostate and colon.

A new study from Washington University has shown that stem cells programmed to act like insulin-secreting beta cells could give Type 1 diabetes patients the treatment they need.

A team of researchers from the University of Michigan has developed a device by which to gauge the flow of drugs through a human kidney and discover better ways to deliver medication to the organ.

Researchers in San Francisco have developed a small ring that rests on the surface of the eye like a contact lens and delivers a glaucoma drug.

A new report from the Cincinnati Children’s Hospital Medical Center in Ohio has shown that, after a self-audit for teenage HPV vaccination rates, the institution was able to “drastically” increase series completion by improving its recommendation process.